New Drug Selinexor (Xpovio) Has Many Risks, Limited Benefits Against Non-Hodgkin Lymphoma

New Drug Selinexor (Xpovio) Has Many Risks, Limited Benefits Against Non-Hodgkin Lymphoma

×
NOW
PLAYING
New Drug Combo Approved for Hard-to-Treat Diffuse Large B-Cell Lymphoma
NOW
PLAYING
Stimulating Your Immune System to Shrink Your Cancer
NOW
PLAYING
Non-Hodgkin Lymphoma Treatment - and Beyond
NOW
PLAYING
Treatment After Relapse: Combatting Non-Hodgkin Lymphoma the Second Time Around
NOW
PLAYING
What's the Risk of Relapse After Non-Hodgkin Lymphoma Treatment?
NOW
PLAYING
Here's What Radiation Is Like for Non-Hodgkin Lymphoma

SurvivorNetTV.
Hope. Science.
Inspiration.

Discover SNTV

Recurrence: Options After Diffuse Large B-Cell Lymphoma Recurrence

SEE MORE   

Recurrence: Options After Diffuse Large B-Cell Lymphoma Recurrence

  • There are several treatment options available if non-Hodgkin lymphoma returns
  • The most common first treatment after relapse is another round of chemotherapy
  • For patients whose cancer does not respond well to chemo, doctors may explore immune-therapies such as CAR-T therapy
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.